TEM— AI Stock Forecast & Price Targets
Published 7/23/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live TEM price forecast →
Tempus AI is a hyper-growth, deeply unprofitable precision-medicine platform trading at $46.96, down 55% from 52-week highs and 20% YTD, with a binary Q2 earnings print in 7 days. The $1.5B all-stock Personalis acquisition adds MRD capability but introduces dilution risk into a 31.67% short float, and the model's own 1d/1wk forecasts have been beaten by the naive baseline — I'd stand aside as HOLD ahead of July 30.
HOLD/AVOID into the July 30 AMC earnings print — this is a binary event with beta 3.46 and ATR of $3.81 (~8% daily range). Do not initiate a swing position. If forced to trade: wait for the print. Invalidation on the downside is a break of the $41.73 52-week low, which would open air to the high-$30s. Resistance-based invalidation on the upside is a decisive reclaim of $50 with volume. Position sizing: zero incremental exposure until post-earnings. IV crush after the report will punish long-premium strategies.
1-6 months: The setup is a coin-flip binary compounded by acquisition integration risk. Base case assumes the July 30 print shows revenue continuation (~30%+ growth) but no margin inflection, and Personalis dilution weighs; price mean-reverts to the $50-55 zone. Bull case requires an upside earnings surprise plus concrete Insights data-licensing monetization detail, driving a squeeze against the 31.67% short float toward $60-65. Bear case: guidance cut or larger-than-expected dilution announcement takes the stock through $42 to the mid-$30s IPO area. Would change my mind: sequential improvement in operating margin toward -10% or better, and clear guidance that OCF turns positive in 2H 2026.
1-3 years: The terminal thesis rests on whether Tempus can monetize its multimodal clinical/molecular data library (Insights) at scale via pharma partnerships (AstraZeneca, GSK, Merck, Recursion) while its diagnostic assay business becomes GAAP profitable. If it works, this is a category-defining precision-medicine data platform with a durable moat in linked oncology data. Biggest structural risk: the $1.32B debt load and persistent cash burn force a dilutive equity raise before profitability arrives, capping equity upside; a secondary risk is that AI-driven diagnostics commoditize faster than expected as competitors (including big pharma in-house efforts) build their own platforms. Personalis MRD integration must actually accelerate revenue, not just consolidate a supplier.
Revenue is scaling impressively — Q1 2026 at $348M with sales Y/Y TTM at +69.8% and Q/Q at +36.1% — but the P&L remains ugly: TTM net income -$303M, operating margin -18.75%, ROE -81.58%, and EPS -$1.72. Gross margin is a respectable ~62-64%, indicating the core assays and data products are structurally profitable, but SG&A and R&D swamp the model. Cash flow quality is deteriorating: Q1 2026 operating cash flow swung to -$73M from +$44M in Q2 2025, and free cash flow was -$83M. The balance sheet shows $521M cash against $1.32B total debt (D/E 3.17), a materially leveraged structure for a money-losing company. The $1.5B all-stock Personalis deal preserves cash but will dilute shareholders meaningfully — share count of 175M is set to rise. At 6.18x P/S and 20x P/B, the market is still paying up for growth, but with forward P/E deeply negative and no path to GAAP profitability visible in the quarterly trajectory, valuation depends entirely on continued top-line acceleration and eventual margin inflection.
The tape is broken across every meaningful timeframe. On the 1h/4h, price has cascaded from $62 in early July to $46.99, breaking through the prior $50-55 support zone that had held for weeks; RSI at 38.16 shows oversold conditions but not yet capitulation. SMA20 at -16.23%, SMA50 at -8.53%, SMA200 at -23.31% — a full stack of downside distances confirming a well-established downtrend. The weekly chart shows a violent decline from $104 highs to $42 lows, with price hugging the lower band of a wide multi-month base. The model's forecast bands are aggressively bullish across all timeframes ($54-70), but the realized accuracy is 35% vs a 70% naive baseline on 1d and 50% vs 100% on 1wk — these forecasts are actively unreliable in the current regime and must be discounted. Key support: $41.73 (52-week low, only 11% below); key resistance: $50 psychological, then $54-55 (prior consolidation floor, now resistance).
The dominant catalyst is the July 20 announcement of a $1.5B all-stock acquisition of Personalis (PSNL), which brings a Medicare-reimbursed MRD (minimal residual disease) test in-house after three years of reselling it. Signal: this vertically integrates a strategic asset in cancer monitoring and eliminates a revenue-share drag, but it comes at a premium and via dilution rather than cash — negative near-term for share supply/demand given the 31.67% short float. Secondary: the OneOme pharmacogenomics launch is a modest incremental revenue lever, not a needle-mover. Coverage from Simply Wall St. flags integration risk and questions whether the bull case is priced in. Noise: TV crawl airtime (121x in 3d, avg 6.89% moves) reflects volatility but not narrative. Retail sentiment is mildly bullish and focused on the Personalis deal mechanics and short positioning — treat as noise, not fact.
- Integration of Personalis MRD test (Medicare-reimbursed) into Tempus's oncology platform — eliminates revenue-share drag and expands the cancer monitoring TAM
- OneOme pharmacogenomics testing solution national launch (July 22) targeting medication dosing/toxicity optimization
- Lens agentic platform expansion for oncology drug development leveraging real-world data with pharma partners (AstraZeneca, GSK, Merck, Recursion, Pathos AI)
- Insights data-licensing revenue stream — de-identified multimodal clinical/molecular datasets sold to life sciences
- Sequential Q/Q revenue growth (+36% Q/Q) suggests continued market adoption of xT/xR core clinical assays
- Binary July 30 AMC earnings with beta 3.46, ATR $3.81, and IV crush — a single print can move the stock 15-25%
- 31.67% short float creates two-way squeeze/cascade risk; stock has fallen 18% in the past week alone
- TTM net loss of -$303M against $521M cash and $1.32B debt implies an eventual dilutive raise if OCF doesn't inflect
- Personalis $1.5B all-stock deal is dilutive to a share count already at 175M — magnitude of dilution not yet reflected
- Model's own forecast reliability is below naive baseline on both 1d and 1wk horizons (35% vs 70%, 50% vs 100%) — do not trust the bullish forecast bands
- Insider selling cluster from CEO ($2.5M across 5 transactions in early July) is a mild negative signal ahead of earnings
- Valuation at 6.18x P/S remains rich for an unprofitable name in a distribution-phase market regime
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord